INTRODUCTION
Omeprazole and pantoprazole are substituted benzimidazole derivatives. These agents, which are activated in the acidic compartment of the parietal cell, inhibit gastric acid secretion by binding to active proton pumps (H + -, K + -ATPase) in the secretory membrane of the parietal cell. The duration of the inhibitory effect of these drugs is due to the prolonged binding to the proton pump. 1±3 Substituted benzimidazole derivatives are rapidly eliminated from plasma and are extensively metabolized by cytochrome P-450 enzymes in the liver. 3, 4 Recently omeprazole became available in a tablet formulation, a Multiple Unit Pellet System (MUPS), which contains a large number of small individually enteric-coated micropellets of omeprazole. MUPS tablets disintegrate rapidly in the stomach and the micropellets may empty more easily into the duodenal channel than conventional enteric-coated tablets. 5, 6 The relatively
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No signi®cant difference in acid-inhibitory effect on day 1. On day 6 median daytime pH was signi®cantly higher with omeprazole MUPS, but the percentages of time spent above pH 3 and 4 were not signi®cantly different. The signi®cant increase in bioavailability of omeprazole may contribute to the increased effect on day 6.
new proton pump inhibitor pantoprazole is administered as an enteric-coated tablet. 7 To make the study double-blind, two tablets of pantoprazole (20 mg) or one capsule of omeprazole (20 mg) were encapsulated using identical hard gelatine capsules. In that study pantoprazole 40 mg was signi®cantly more effective than omeprazole 20 mg in raising 24-h median pH and daytime median pH both after single and repeated administration. However, with respect to healing rate, omeprazole 20 mg capsules and pantoprazole 40 mg tablets have similar ef®cacy in the treatment of re¯ux oesophagitis and duodenal ulcer. 8, 9 The aim of the present study was to compare the pharmacodynamic effect on gastric pH of omeprazole MUPS 20 mg with pantoprazole 40 mg enteric-coated tablets following single (day 1) and repeated (day 6) oral administration and to describe the pharmacokinetics of both medications on these days.
METHODS

Subjects
Healthy subjects, between 18 and 40 years old, with normal physical examination and laboratory screening tests (haemoglobin, white blood cell total count, serum glucose, serum creatinine, total bilirubin, serum alkaline phosphatase, serum ASAT and/or ALAT) were recruited for the study. They were eligible for inclusion if their H. pylori serology (ELISA) was negative, and if their 24-h baseline gastric pH measurement was < pH 4 for more than 70% of the time (more than 16.8 h) at the time of enrolment. 10 Individuals were excluded from the study if they were pregnant, if they had gastrointestinal disorders, which might impair drug absorption, if they had a body weight more than 15% from ideal, and if they had a history of alcohol or drug abuse. With the exception of oral contraceptives and the occasional use of paracetamol (acetaminophen) the subjects took no medication other than the study medication. Smokers were not excluded, but were instructed to refrain from smoking during the pHmonitoring studies. All subjects gave written informed consent and the study was conducted in accordance with the Declaration of Helsinki. The local Ethics Committee approved the study protocol.
Study protocol
This was a randomized, two-way crossover, investigatorblind study performed in the Leyenburg Hospital from April 1998 to October 1998. The study was designed to include 16 healthy H. pylori-negative subjects whose intragastric pH was below pH 4 for more than 70% of the time during a 24-h baseline period.
After inclusion each subject was assigned to one of the two 6-day dosing periods during which the subject received either omeprazole MUPS 20 mg o.d. or pantoprazole 40 mg o.d. Dosing periods were separated by washout periods of at least 14 days. The effect of both drugs on gastric acidity was assessed by 24-h intragastric pH monitoring on day 1 and day 6 of administration. During the days of pH monitoring subjects stayed at a special research room in the clinic. Subjects arrived at the pH laboratory of the clinic by 08:00 hours. A venous catheter was inserted and the ®rst blood sample was drawn. A nostril was anaesthetized with xylocaine spray and the`personal' pH-measuring assembly was inserted and positioned, such that the pH electrode was located in the gastric corpus, 5±10 cm below the oesophagogastric junction as determined by the pHdrop. The insertion depth was recorded. In subsequent pH studies in the same subject, this same insertion depth was used. Recordings started at 08:30 hours. After the pH recording was started, the subjects took the ®rst dose of the study medication immediately before the standard breakfast. Standard meals (breakfast, lunch and dinner) were prepared in the hospital and subjects were instructed to eat their lunch at 14:00 hours, and dinner at 18:00 hours. Blood samples (5 mL) for determination of omeprazole and pantoprazole plasma concentrations were drawn at pre-dose and at 30, 45, 60, 90, 120, 150, 180, 210 min, and at 4, 5, 6, 7, 8 and 9 h after dose. The venous catheter was removed after the last blood sample. From 23:00 hours the subjects remained in fasting condition and slept. They arose again between 07:00 and 07:30 hours the next day. The pH electrode was removed at 08:30 hours and the position of the assembly was checked prior to removal. On the pH measurement days the use of tap water, tea and noncarbonated mineral water was restricted to a total of 2 L. Other beverages were not permitted. Plasma concentrations of omeprazole and pantoprazole were determined by means of liquid chromatography techniques at Bio-analytical Chemistry, Astra Ha Èssle AB, Mo Èlndal, Sweden.
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Data analysis and statistical evaluation pH data Twenty-four-hour pH-metry was performed as previously described. 12 Evaluation of pH data was performed as previously described. 12, 13 Data were analysed using the SPSS statistical package. Wilcoxon's matched pairs signed rank test was used for comparison between treatment regimens. Median pH values over the whole 24-h period, day-and night-time, and cumulative percentages of time during which pH was above thresholds 3 and 4 over these time periods, were compared. The signi®cance level of each test was set at 0.05 (twosided). P-values are presented as calculated for each test, no correction being made for multiple testing.
Pharmacokinetic data
Pharmacokinetic parameters were derived by noncompartmental analysis using WinNonlin software (version 3.1, Scienti®c Consulting Inc.). For each individual the following parameters were derived separately on day 1 and 6 of drug administration: time prior to the ®rst measurable concentration (T lag ), time of maximum observed concentration (T max ), and the maximum observed concentration (C max ). The terminal rate constant (k) was determined by log-linear regression of the terminal phase of the plasma concentration± time curve. The terminal half-life (T ) was calculated as follows: T 0.693/k. The area under the concentration±time curve (AUC) and the area under the ®rst moment curve (AUMC) were estimated by the linearlogarithmic trapezoidal method up to the last measured data point with extrapolation to in®nity using k. The ratio of plasma clearance and bioavailability (Cl/F) was calculated by dividing the dose by the AUC. The ratio of the volume of distribution based on the terminal phase and bioavailability (V/F) was calculated by dividing Cl/ F by k. Mean residence time (MRT) was the ratio of AUMC and AUC.
Differences in pharmacokinetic parameters between day 1 and 6 and differences in pharmacokinetic parameters between omeprazole and pantoprazole were evaluated using Wilcoxon's matched pairs signed rank test. The level of signi®cance was set at 0.05.
RESULTS
Eighteen healthy subjects (11 women, seven men, aged 20±30 years) were screened. The serology (ELISA) was positive in one subject. One subject discontinued with the study after the baseline measurement. Sixteen subjects (nine women, seven men) with a mean age of 24.7 years (range 21.4±30 years), a mean weight of 73 kg (range 55±97 kg) and a mean height of 175.6 cm (range 157±192 cm) ful®lled the inclusion criteria and were randomized. Both drugs were welltolerated and there were no clinically relevant adverse events. Group median pH-time curves and interquartile ranges (25th±75th percentile) for baseline and the two treatment regimens during the ®rst (day 1) and second (day 6) 24-h recording period are shown in Figure 1 . The percentages of time spent above pH thresholds 1±7 for baseline and the two treatment regimens during the entire recording period, day-and night-time on day 1 and day 6 are shown in Figure 2 . Inter-individual variation in response to the different dosing regimens is shown in Figure 3 . Median pH values and median percentages of time spent above pH thresholds 3 and 4, for baseline and the two treatment regimens during the entire recording period, and day-and night-time on day 1 and day 6 are shown in Table 1 . Differences in pharmacokinetic parameters between day 1 and 6 and differences in pharmacokinetic parameters between omeprazole and pantoprazole are displayed in Table 2 . Median plasma concentrations of omeprazole and pantoprazole on day 1 and day 6 of administration are shown in Figure 4 . Compared to baseline, both drugs signi®cantly increased median gastric pH and the percentages of time spent above pH 3 and 4 over the whole ®rst 24 h of administration. During the night-time period, percentages of time above pH thresholds 3 and 4 were not signi®cantly increased with pantoprazole. There were no signi®cant differences between omeprazole and pantoprazole in median pH values or time spent above pH thresholds 3 and 4 for either the whole ®rst 24 h period or day-or night-time period. On day 6 of administration, median pH over the day period was signi®cantly higher with omeprazole MUPS, but there were no signi®cant differences between omeprazole and pantoprazole in the percentages of time spent above pH thresholds 3 and 4. On day 6 of omeprazole administration, C max , T , and AUC were signi®cantly increased in comparison with the values on day 1, whereas Cl/F and V/F were reduced. No pharmacokinetic differences were observed between day 1 and day 6 of administration for pantoprazole. T lag and T of omeprazole were smaller than the corresponding values of pantoprazole. No signi®cant differences were observed for T max and MRT on day 1 and day 6, between omeprazole and pantoprazole.
DISCUSSION
This direct comparative study in H. pylori-negative subjects showed no signi®cant differences between omeprazole MUPS 20 mg and pantoprazole 40 mg after single dose administration. After repeated administration median pH over the day period was signi®cantly higher with omeprazole MUPS, but there were no signi®cant differences between omeprazole and pantoprazole in the percentages of time spent above pH thresholds 3 and 4. The pharmacokinetic parameters in this study are consistent with data obtained in other studies for both omeprazole and pantoprazole. 6, 14, 15 The time interval between dosing and the ®rst measurable concentration of omeprazole MUPS was signi®cantly shorter than the lag time of pantoprazole, but there was no signi®cant difference in acid-inhibitory effect during the daytime on day 1 of administration. AUC and C max of omeprazole MUPS 20 mg were signi®cantly higher on day 6 than on day 1 (74% and 68%, respectively). This effect has been described earlier. 14, 15 Possible reasons for the increase in bioavailability upon repeated administration may be saturation of ®rst-pass metabolism and a stepwise decrease in gastric acid delivered into the duodenum. 16 The increased bioavailability and decreased clearance is re¯ected in the decrease in V/F and Cl/F. For pantoprazole, AUC and C max following repeated administration were comparable to those after the ®rst dose, indicating that bioavailability remained constant after the ®rst dose. The clinical relevance of the increase in AUC with repeated dosing of omeprazole remains unclear. However, it can be speculated that the increase in AUC may contribute to the increase in the pharmacodynamic effect on day 6 of administration.
In the present study median gastric pH on day 6 over the daytime period was signi®cantly higher with omeprazole MUPS. In a previous direct comparative study of omeprazole MUPS 20 mg and pantoprazole 40 mg, median gastric pH on day 7 of administration was not signi®cantly different. However, on day 1, median gastric pH was signi®cantly higher with pantoprazole. 17 The clinical relevance of signi®cant differences in median pH over time periods is limited, when percentages of time spent above pH thresholds 3 and 4 in those time periods do not differ signi®cantly. According to the studies of Burget, Bell and Howden et al., healing of peptic ulcer disease or erosive oesophagitis with antisecretory drugs is correlated with both the duration of gastric acid suppression over the 24-h period and the degree of gastric acid suppression.
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The percentage of time spent above pH threshold 3 is more important for ulcer healing than further elevation of gastric pH. Healing rates at 8 weeks of (erosive) re¯ux oesophagitis are directly correlated with the duration of gastric acid suppression above pH 4. In our study there is no signi®cant difference between omeprazole MUPS 20 mg and pantoprazole 40 mg in the percentages of time spent above pH 3 and 4 on day 1 and day 6 of administration. The percentages of time spent above pH 3 and 4 on day 6 of omeprazole 20 mg MUPS administration are comparable with the values of these variables found in a previous study with omeprazole 20 mg capsules. 12 This indicates that the omeprazole 20 mg MUPS formulation performs as well as the omeprazole 20 mg capsules formulation. Therefore, it is not surprising that in clinical studies omeprazole 20 mg capsules and pantoprazole 40 mg tablets have similar ef®cacy with respect to healing rates in the treatment of duodenal ulcer and re¯ux oesophagitis. 8, 9 Furthermore, more recently Mulder et al. showed that omeprazole MUPS 20 mg and pantoprazole 40 mg have similar ef®cacy in symptom relief at 4 weeks in the treatment of re¯ux oesophagitis grade I to IV. 21 In conclusion, this direct comparative study demonstrates that the acid-inhibitory effects of omeprazole MUPS 20 mg and pantoprazole 40 mg are not signi®-cantly different on day 1 of administration. On day 6 of administration, median daytime pH was signi®cantly higher with omeprazole MUPS. The clinical relevance of this difference is limited, since percentages of time spent above pH 3 and 4 in this period were not signi®cantly different. The signi®cant increase in bioavailability of omeprazole on day 6 of administration may contribute to the increased acid-inhibitory effect after repeated administration. 
